JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, reported today interim data from an ongoing Phase 1 study designed to assess and compare the pharmacokinetic (PK) and early pharmacodynamic (PD) profile of current and several next generation compositions of its oral peptide platform (NCT05965167).
EB613 Continues to Display an Optimal Profile as First-in-Class Oral PTH(1-34) Peptide for Osteoporosis
The Phase 1 study first compared the PK profile of Entera’s Phase 3 candidate, oral once-daily PTH(1-34) mini-tablets (EB613, a.k.a. EBP05 formulation) with subcutaneous (SC) PTH(1-34) 20 g (Forteo®). Consistent with previously reported PK and bioavailability data, EBP05 induced a rapid and dose-proportional increase in plasma drug concentrations of PTH(1-34) at all doses tested. The target bioavailability of PTH (1-34) with EB613 at doses of 1.5 mg and 2.5 mg, covering the dose range planned for phase 3 was met. Additionally, EB613 exhibited consistent and statistically significant (p